<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20181">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02844179</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00105810 -1</org_study_id>
    <nct_id>NCT02844179</nct_id>
  </id_info>
  <brief_title>(+)-Alpha-Dihydrotetrabenazine Phase I</brief_title>
  <official_title>(+)-Alpha-Dihydrotetrabenazine Phase I</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirk A. Frey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adeptio Pharmaceuticals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is intended to determine the initial safety and tolerability of single
      oral doses of the drug (+)-alpha-dihydrotetrabenaxine (HTBZ) in normal volunteers. HTBZ is
      believed to be the active ingredient in the FDA-approved drug tetrabenazine (TBZ, brand name
      Xenazine), prescribed for treatment of involuntary movements in patients with Huntington's
      chorea. TBZ is a mixture of closely-related compounds (isomers) and is readily metabolized
      (converted) in the human body to HTBZ and related isomers. Investigators believe that HTBZ,
      the drug to be studied in this research, is the active ingredient in TBZ. The present study
      will confirm safety and tolerability of HTBZ and will investigate its expected effects on
      brain sites that are the target of TBZ therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VMAT2 occupancy by HTBZ determined by positron emission tomography (PET) scanning</measure>
    <time_frame>60 minutes post-administration of HTBZ</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose administration of (+)-alpha-Dihydrotetrabenazine (HTBZ), escalating dosage amounts 7.5 - 30 mg orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTBZ</intervention_name>
    <arm_group_label>dose escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  able to provide informed consent

        Exclusion Criteria:

          -  pregnant or lactating female subjects

          -  Subjects taking medications that interfere with VMAT2 (ex amphetamine)

          -  History of significant neurologic or psychiatric conditions

          -  Significant active medical conditions

          -  Alcohol or illicit substance use or dependence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kirk A Frey, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Minderovic, BS</last_name>
    <phone>(734) 998-8420</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of Michigan hospitals</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 24, 2017</lastchanged_date>
  <firstreceived_date>July 20, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Kirk A. Frey</investigator_full_name>
    <investigator_title>Professor of Radiology</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
